Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
DCTH 
Delcath Systems Inc (DCTH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/13/2025: DCTH (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $23.47
1 Year Target Price $23.47
| 4 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 117.72% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 303.34M USD | Price to earnings Ratio 286.33 | 1Y Target Price 23.47 |
Price to earnings Ratio 286.33 | 1Y Target Price 23.47 | ||
Volume (30-day avg) 6 | Beta 0.41 | 52 Weeks Range 8.33 - 18.23 | Updated Date 11/13/2025 |
52 Weeks Range 8.33 - 18.23 | Updated Date 11/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.03 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-04 | When - | Estimate -0.03 | Actual 0.02 |
Profitability
Profit Margin 1.51% | Operating Margin (TTM) -1.89% |
Management Effectiveness
Return on Assets (TTM) 4.72% | Return on Equity (TTM) 1.94% |
Valuation
Trailing PE 286.33 | Forward PE 12.77 | Enterprise Value 216457249 | Price to Sales(TTM) 3.81 |
Enterprise Value 216457249 | Price to Sales(TTM) 3.81 | ||
Enterprise Value to Revenue 2.72 | Enterprise Value to EBITDA 34.96 | Shares Outstanding 35313718 | Shares Floating 34361307 |
Shares Outstanding 35313718 | Shares Floating 34361307 | ||
Percent Insiders 2.7 | Percent Institutions 52 |
Upturn AI SWOT
Delcath Systems Inc
Company Overview
History and Background
Delcath Systems, Inc. is a specialty pharmaceutical company focused on oncology. It was founded in 1989. The company has focused on developing and commercializing proprietary products for the treatment of cancer, particularly cancers affecting the liver.
Core Business Areas
- CHEMOSAT Delivery System: The CHEMOSAT Delivery System is Delcath's primary focus, used for regional chemotherapy in the liver. It aims to isolate the liver and deliver high doses of chemotherapy directly to the tumor while minimizing systemic exposure.
Leadership and Structure
Delcath Systems Inc's leadership team consists of Gerard Michel (Chief Executive Officer), Anthony Price (Chief Financial Officer). The organizational structure consists of functional departments that oversee R&D, commercial operations, and regulatory affairs.
Top Products and Market Share
Key Offerings
- CHEMOSAT Delivery System: CHEMOSAT is a device that allows for high-dose chemotherapy to be delivered directly to the liver, specifically for patients with unresectable hepatic metastases from ocular melanoma (mOM). Competitors are systemic chemotherapy regimens, surgical resection, and other locoregional therapies such as transarterial chemoembolization (TACE) and radioembolization (Y-90). Revenue depends on the number of procedures performed. Specific market share data is not readily available.
Market Dynamics
Industry Overview
The industry includes companies developing and marketing cancer therapies, particularly those focused on localized drug delivery and liver-directed treatments. The market is competitive and heavily regulated.
Positioning
Delcath Systems Inc. is positioned in the niche of liver-directed chemotherapy. Its competitive advantage is the CHEMOSAT system's ability to deliver high doses of chemotherapy with reduced systemic toxicity.
Total Addressable Market (TAM)
The total addressable market for liver-directed cancer therapies is substantial, estimated in the billions of dollars globally. Delcath is focused on a subset of this market, specifically mOM and other hepatic metastases. Their TAM is dependent on the number of eligible patients and the adoption rate of CHEMOSAT.
Upturn SWOT Analysis
Strengths
- Proprietary CHEMOSAT technology
- Targeted drug delivery
- Potential for reduced systemic toxicity
- FDA approved device
Weaknesses
- Limited product portfolio
- Dependence on a single product
- Small market capitalization
- History of financial losses
Opportunities
- Expansion into other cancer types
- Partnerships with larger pharmaceutical companies
- Geographic expansion
- Technological advancements in drug delivery
Threats
- Competition from alternative therapies
- Regulatory hurdles
- Reimbursement challenges
- Potential for product obsolescence
Competitors and Market Share
Key Competitors
- MRK
- AZN
- BMY
- GILD
Competitive Landscape
Delcath has a niche product, but faces competition from large pharmaceutical companies offering systemic therapies. Its advantage lies in targeted drug delivery, while its disadvantage is its smaller size and limited resources compared to its competitors.
Growth Trajectory and Initiatives
Historical Growth: Dependent on CHEMOSAT adoption and market penetration.
Future Projections: Analyst estimates vary and must be sourced from financial news outlets and analyst reports.
Recent Initiatives: Recent initiatives often include clinical trials, regulatory submissions, and commercial expansion efforts. Specifics are available in company press releases and SEC filings.
Summary
Delcath Systems is a niche pharmaceutical company with a proprietary technology for liver-directed chemotherapy. Its strength lies in its targeted approach, reducing systemic toxicity. However, it faces challenges due to its limited product portfolio, dependence on CHEMOSAT, and competition from larger pharmaceutical players. Future growth depends on expanding the use of CHEMOSAT and exploring new applications.
Similar Stocks
Sources and Disclaimers
Data Sources:
- SEC filings (10-K, 10-Q), company press releases, financial news outlets, analyst reports.
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share estimates are approximate. Financial data should be verified through official SEC filings.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Delcath Systems Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2018-05-29 | CEO & Director Mr. Gerard J. Michel MBA, MS | ||
Sector Healthcare | Industry Medical Devices | Full time employees 96 | Website https://www.delcath.com |
Full time employees 96 | Website https://www.delcath.com | ||
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1987 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.